IP Library › Granted Patent US 12,220,235
Granted Patent B2
US 12,220,235 · App. 16/774,909 · Granted Feb 11, 2025

Analyte sensors and sensing methods for dual detection of glucose and ethanol

Inventors: Tianmei Ouyang (Fremont, CA); Benjamin J. Feldman (Berkeley, CA); Hyun Cho (Berkeley, CA); Lam N. Tran (Dublin, CA); Stephen Oja (Alameda, CA); Namvar Kiaie (San Jose, CA)
Assignee: Abbott Diabetes Care Inc.
A61B5/14865A61B5/14532A61B5/4845B60K28/06C12Q1/30C12Q1/32B60K28/063B60K28/066
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,235
App. No.
16/774,909
Filed
Jan 28, 2020
Granted
Feb 11, 2025
Kind
B2
Art Unit
3791
USPC
600/347
Abstract

Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.

Claims (34)

1. An analyte sensor comprising:

a) a working electrode;

b) a glucose-responsive active area disposed upon a surface of the working electrode, the glucose-responsive active area comprising a glucose-responsive active enzyme capable of generating a first signal at the working electrode proportional to a glucose concentration;

c) an ethanol-responsive active area comprising:

i) a first active area disposed directly upon the surface of the working electrode spaced apart from the glucose-responsive active area, the first active area comprising xanthine oxidase and an electron transfer agent, in amounts sufficient to react with acetaldehyde to generate a second signal at the working electrode proportional to an alcohol concentration; and

ii) a second active area isolated from the working electrode, the second active area comprising glucose oxidase and catalase in amounts sufficient to form acetaldehyde upon exposure to ethanol;

d) a first membrane permeable to acetaldehyde disposed upon the first active area; and

e) a second membrane permeable to glucose and ethanol disposed upon the glucose-responsive active area and the second active area,

wherein the second active area is disposed directly upon the first membrane, and

wherein the sensor is configured to be partially inserted into a user's skin.

2. The analyte sensor of claim 1 , wherein the first and second membranes comprise a polyvinylpyridine, a polyvinylimidazole, or any copolymer thereof.

3. The analyte sensor of claim 1 , wherein the first membrane comprises polyvinylpyridine and the second membrane comprises polyvinylpyridine-co-styrene.

4. The analyte sensor of claim 1 , wherein the xanthine oxidase is covalently bound to a first polymer, and the glucose oxidase is covalently bound to a second polymer.

5. The analyte sensor of claim 4 , wherein the electron transfer agent is covalently bound to the first polymer.

6. The analyte sensor of claim 5 , wherein the electron transfer agent comprises an osmium complex.

7. The analyte sensor of claim 1 , wherein the first active area further comprises catalase.

8. The analyte sensor of claim 1 , wherein the glucose-responsive enzyme is glucose oxidase or glucose dehydrogenase.

9. The analyte sensor of claim 1 , further comprising:

a control module in communication with the analyte sensor and an electrical system of a vehicle, the control module including a computer system programmed to receive and process data provided by the analyte sensor,

wherein operation of the vehicle is controlled or disabled by the computer system when a real-time measured analyte level of the operator crosses a predetermined safe threshold.

10. The analyte sensor of claim 1 , wherein the glucose-responsive active area further comprises a second electron transfer agent.

11. A method comprising:

exposing an analyte sensor to a body fluid comprising at least one of glucose and ethanol, the analyte sensor comprising:

a) a working electrode;

b) a glucose-responsive active area disposed upon a surface of the working electrode, the glucose-responsive active area comprising a glucose-responsive active enzyme capable of generating a first signal at the working electrode proportional to a glucose concentration;

c) an ethanol-responsive active area comprising:

i) a first active area disposed directly upon the surface of the working electrode spaced apart from the glucose-responsive active area, the first active area comprising xanthine oxidase and an electron transfer agent, in amounts sufficient to react with acetaldehyde to generate a second signal at the working electrode proportional to an alcohol concentration; and

ii) a second active area isolated from the working electrode, the second active area comprising glucose oxidase and catalase in amounts sufficient to form acetaldehyde upon exposure to ethanol;

d) a first membrane permeable to acetaldehyde disposed upon the first active area;

e) a second membrane permeable to glucose and ethanol disposed upon the glucose-responsive active area and the second active area, and

detecting a first signal proportional to a glucose concentration and the second signal proportional to an ethanol concentration,

wherein the second active area is disposed directly upon the first membrane, and

wherein the sensor is configured to be partially inserted into a user's skin.

12. The method of claim 11 , wherein the glucose-responsive active area further comprises a second electron transfer agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2020
From: OUYANG, TIANMEI; FELDMAN, BENJAMIN J.; CHO, HYUN; TRAN, LAM N.; OJA, STEPHEN; SLOAN, MARK K.; KUMAR, ASHWIN; KIAIE, NAMVAR; LOVE, MICHAEL R.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 051989/0421 →
Continuity (3)
Provisional Application 62884841 · Aug 9, 2019
Provisional Application 62797566 · Jan 28, 2019
Related Publication 20200237277A1 · Jul 30, 2020
References Cited (107)
US 5264105A · Gregg et al. · 1993 [cited by applicant]
US 5696314A · McCaffrey et al. · 1997 [cited by applicant]
US 5792621A · Verostko · 1998 [cited by applicant]
US 6127138A · Ishimaru · 2000 [cited by examiner]
US 6134461A · Say et al. · 2000 [cited by applicant]
US 6241863B1 · Monbouquette · 2001 [cited by applicant]
US 6605200B1 · Mao et al. · 2003 [cited by applicant]
US 6605201B1 · Mao et al. · 2003 [cited by applicant]
US 6736957B1 · Forrow · 2004 [cited by applicant]
US 7501053B2 · Karinka et al. · 2009 [cited by applicant]
US 7563588B2 · Gao et al. · 2009 [cited by applicant]
US 7754093B2 · Forrow et al. · 2010 [cited by applicant]
US 8268143B2 · Liu et al. · 2012 [cited by applicant]
US 8444834B2 · Liu et al. · 2013 [cited by applicant]
US 8545693B2 · McColl et al. · 2013 [cited by applicant]
US 10136816B2 · Bernstein et al. · 2018 [cited by applicant]
US 20010003045A1 · Davis et al. · 2001 [cited by applicant]
US 20030100821A1 · Heller et al. · 2003 [cited by applicant]
US 20060004272A1 · Shah · 2006 [cited by applicant]
US 20070027385A1 · Brister et al. · 2007 [cited by applicant]
US 20070213611A1 · Simpson et al. · 2007 [cited by applicant]
US 20080179187A1 · Ouyang et al. · 2008 [cited by applicant]
US 20080319295A1 · Bernstein et al. · 2008 [cited by applicant]
US 20090294306A1 · Feldman et al. · 2009 [cited by applicant]
US 20100116691A1 · Papadimitrakopoulos · 2010 [cited by examiner]
US 20100213057A1 · Feldman et al. · 2010 [cited by applicant]
US 20100230285A1 · Hoss et al. · 2010 [cited by applicant]
US 20100267161A1 · Wu et al. · 2010 [cited by applicant]
US 20110046467A1 · Simpson et al. · 2011 [cited by applicant]
US 20110213225A1 · Bernstein et al. · 2011 [cited by applicant]
US 20120132525A1 · Liu et al. · 2012 [cited by applicant]
US 20120150005A1 · Hoss et al. · 2012 [cited by applicant]
US 20120181189A1 · Merchant · 2012 [cited by applicant]
US 20120186997A1 · Li et al. · 2012 [cited by applicant]
US 20120283537A1 · Petisce et al. · 2012 [cited by applicant]
US 20130131478A1 · Simpson et al. · 2013 [cited by applicant]
US 20130211219A1 · Coppeta et al. · 2013 [cited by applicant]
US 20130324820A1 · Petillo · 2013 [cited by examiner]
US 20140054171A1 · Feldman · 2014 [cited by examiner]
US 20140127728A1 · Wilsey · 2014 [cited by applicant]
US 20140176338A1 · He et al. · 2014 [cited by applicant]
US 20140262776A1 · Martin et al. · 2014 [cited by applicant]
US 20140262777A1 · Zhao et al. · 2014 [cited by applicant]
US 20150207796A1 · Love et al. · 2015 [cited by applicant]
US 20160319232A1 · Noritomi · 2016 [cited by examiner]
US 20170156652A1 · Qiang · 2017 [cited by applicant]
US 20170315077A1 · Rao et al. · 2017 [cited by applicant]
US 20180116604A1 · Newberry · 2018 [cited by examiner]
US 20190004005A1 · Oja et al. · 2019 [cited by applicant]
US 20190271658A1 · Haneda et al. · 2019 [cited by applicant]
US 20190274598A1 · Scott et al. · 2019 [cited by applicant]
US 20200069226A1 · Hahn et al. · 2020 [cited by applicant]
US 20200237275A1 · Feldman et al. · 2020 [cited by applicant]
US 20200237276A1 · Oja et al. · 2020 [cited by applicant]
US 20200241015A1 · Ouyang et al. · 2020 [cited by applicant]
US 20210137431A1 · Oja et al. · 2021 [cited by applicant]
US 20210254120A1 · Plumeré · 2021 [cited by examiner]
US 20220168727A1 · Baldwa · 2022 [cited by applicant]
US 20230118818A1 · Feldman et al. · 2023 [cited by applicant]
US 20230119512A1 · Feldman et al. · 2023 [cited by applicant]
US 20230121101A1 · Feldman et al. · 2023 [cited by applicant]
US 20230121367A1 · Feldman et al. · 2023 [cited by applicant]
US 20230121769A1 · Feldman et al. · 2023 [cited by applicant]
US 20230122702A1 · Feldman et al. · 2023 [cited by applicant]
US 20230123384A1 · Feldman et al. · 2023 [cited by applicant]
US 20230128038A1 · Feldman et al. · 2023 [cited by applicant]
CN 101849180B · 2017 [cited by applicant]
JP 2007290504A · 2007 [cited by applicant]
JP 2010517054A · 2010 [cited by applicant]
JP 2010530790A · 2010 [cited by applicant]
JP 2013504053A · 2013 [cited by applicant]
JP 2014503080A · 2014 [cited by applicant]
JP 2018029983A · 2018 [cited by applicant]
WO 2005040404A1 · 2005 [cited by applicant]
WO WO2009105337A2 · 2009 [cited by applicant]
WO WO2011030093A1 · 2011 [cited by applicant]
D'Allegro, Joe. “Soon Your Car Will Know When You Are Having a Heart Attack—and Know How to React.” CNBC, Nov. 17, 2017, www.cnbc.com/2017/11/17/cars-will-know-when-youre-having-a-heart-attack-and-how-to-react.html. Acc… [cited by examiner]
Guiseppi-Elie et al, “Design of a Subcutaneous Implantable Biochip for Monitoring of Glucose and Lactate,” IEEE Sensors Journal, Jun. 1, 2005. [cited by applicant]
C.S. Pundir et al, “Biosensing Methods for Determination of Creatinine: A Review,” Biosensors and Bioelectronics Journal, Nov. 19, 2018. [cited by applicant]
ISR/WO for PCT/US2020/015400 related to the present application and dated Apr. 9, 2020. [cited by applicant]
Cardosi, M., et al., “Amperometric Glucose Sensors for Whole Blood Measurement Based on Dehydrogenase Enzymes,” in [cited by applicant]
Office Action mailed Sep. 17, 2021, in U.S. Appl. No. 16/774,835, Feldman, B., et al., filed Jan. 28, 2020, 21 pages. [cited by applicant]
Office Action mailed Apr. 18, 2022, in U.S. Appl. No. 16/774,835, Feldman, B., et al., filed Jan. 28, 2020, 24 pages. [cited by applicant]
Office Action mailed Jun. 23, 2022, in U.S. Appl. No. 16/774,841, Oja, S., et al., filed Jan. 28, 2020, 10 pages. [cited by applicant]
Office Action mailed Sep. 1, 2022, in U.S. Appl. No. 16/582,583, Ouyang, T., et al., filed Sep. 25, 2019, 20 pages. [cited by applicant]
Office Action mailed Nov. 16, 2022, in U.S. Appl. No. 16/774,841, Oja, S., et al., filed Jan. 28, 2020, 10 pages. [cited by applicant]
Office Action mailed Nov. 25, 2022, in U.S. Appl. No. 17/151,274, Oja, S., et al., filed Jan. 18, 2021, 13 pages. [cited by applicant]
Office Action mailed Mar. 2, 2023, in U.S. Appl. No. 16/774,835, Feldman, B., et al., filed Jan. 28, 2020, 14 pages. [cited by applicant]
Shi, G., et al., “The study of Nafion/xanthine oxidase/Au colloid chemically modified biosensor and its application in the determination of hypoxanthine in myocardial cells in vivo,” Analyst 127(3):396-400, The Royal So… [cited by applicant]
Mueller, S., et al., “The GOX/CAT system: A novel enzymatic method to independently control hydrogen peroxide and hypoxia in cell culture,” Adv Med Sci 54(2):121-35, Medical University of Bialystok, Poland (2009). [cited by applicant]
Burmeister, J., et al., “Self-referencing ceramic-based multisite microelectrodes for the detection and elimination of interferences from the measurement of L-glutamate and other analytes,” Anal Chem 73(5):1037-42, Amer… [cited by applicant]
Monteiro, T., et al., “Construction of effective disposable biosensors for point of care testing of nitrite,” Talanta 142:246-51, Elsevier, Netherlands (Sep. 2015). [cited by applicant]
Final Office Action mailed Apr. 19, 2023, in U.S. Appl. No. 16/582,583, 18 pages. [cited by applicant]
Office Action mailed Oct. 3, 2023, in U.S. Appl. No. 16/582,583, 21 pages. [cited by applicant]
Office Action mailed Sep. 12, 2023, in U.S. Appl. No. 16/774,835, 16 pages. [cited by applicant]
Notice of Allowance mailed Aug. 16, 2023, in U.S. Appl. No. 16/774,841, 10 pages. [cited by applicant]
Office Action mailed Sep. 7, 2023, in U.S. Appl. No. 17/151,274, 13 pages. [cited by applicant]
Office Action mailed Sep. 22, 2023, in U.S. Appl. No. 17/819,099, 24 pages. [cited by applicant]
Final Office Action mailed May 16, 2024, in U.S. Appl. No. 16/582,583, 21 pages. [cited by applicant]
Non-Final Office Action mailed Apr. 15, 2024, in U.S. Appl. No. 16/774,835, 16 pages. [cited by applicant]
Non-Final Office Action mailed Feb. 15, 2024, in U.S. Appl. No. 18/068,072, 13 pages. [cited by applicant]
Non-Final Office Action mailed Jun. 18, 2024, in U.S. Appl. No. 18/068,704, 14 pages. [cited by applicant]
Non-Final Office Action mailed Jul. 15, 2024, in U.S. Appl. No. 18/068,860, 13 pages. [cited by applicant]
Non-Final Office Action mailed Feb. 29, 2024, in U.S. Appl. No. 18/068,019, 12 pages. [cited by applicant]
Non-Final Office Action mailed Jan. 31, 2024, in U.S. Appl. No. 18/068,834, 10 pages. [cited by applicant]
Notice of Allowance mailed Feb. 7, 2024, in U.S. Appl. No. 17/151,274, 8 pages. [cited by applicant]
Non-Final Office Action mailed Mar. 5, 2024, in U.S. Appl. No. 18/068,714, 14 pages. [cited by applicant]